AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03470987 — intervention group
Intervention type: PROCEDURE
Intervention: Phase I Periodontal therapy
Description: Oral hygiene instuction, scaling and root planning
Study NCT03470987 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Metabolic control
Description: Calorie restricted diet
Study NCT02967016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Actigraph
Description: following delivery a ActiGraph will be offered to patients to track their steps
Study NCT01391442 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood and urine samples
Description: 58 ml of blood 120 ml of urine
Study NCT01391442 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: blood sample
Description: 11 ml of blood
Study NCT01391442 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cardiovascular assessment
Description: echography, echodoppler, measure of blood pressure...
Study NCT01391442 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stanislas ancillary study : MRI examination with GRICS technique
Study NCT03784963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids
Description: Patients will receive 4 grams fish oil once daily
Study NCT03784963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of care
Study NCT03176030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Fortified Foods
Description: The intervention under study is the provision of between-meal fortified foods (enhanced with protein, energy, and micronutrients) and meal supplementation where meals are poorly consumed. Foods will include both savory and sweet foods with different flavors. Foods will be matched as closely as possible in protein and energy and are calculated to provide typically 210 kcal and 5g protein per item. The volume / weight of the foods are standardized to be of relatively small portion size, such as 100 ml for ice-creams, 40 g for cakes and biscuits, and 100 ml for soup. Some of the products will be supplemented with micronutrients particularly needed by older adults, such as Vitamins (C, D, folic acid, B2, B6) and calcium at one third of the Dietary Reference Values (DRV) per portion. The aim is to achieve a daily consumption of two additional fortified food items.
Study NCT01362491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Sodium
Description: Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
Study NCT01362491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ibuprofen
Description: Single-dose of standard ibuprofen tablets (400mg)
Study NCT01362491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose of placebo
Study NCT04653350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Exercises
Description: Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
Study NCT04653350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Exercises
Description: Supervised general fitness exercises including general body stretches, treadmill walking, mild to moderate intensity progressive resistance training \& balance exercises will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months
Study NCT02491736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: 2.5% ketoprofen gel
Study NCT02491736 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel
Study NCT01090024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: BI 671800
Study NCT01090024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 671800
Study NCT01159158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nateglinide
Description: Nateglinide Tablets 120 mg
Study NCT01159158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nateglinide
Description: Nateglinide Tablets 120 mg
Study NCT03667547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 600 mg tablet
Study NCT01779882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
Description: Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
Study NCT01779882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
Description: Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
Study NCT04428554 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental arm
Description: Consolidative radiotherapy (pelvic irradiation and/or metastases irradiation) + standard of care +/- previous transurethral resection of bladder tumor
Study NCT04090320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CATERPILLAR™ Arterial Embolization Device
Description: Placement of the CATERPILLAR™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
Study NCT02037243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Public Health Intervention with Water Treatment
Description: Compound level meeting
Study NCT02037243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Public Health Intervention with Water Treatment & Hand Washing
Description: Compound level meeting
Study NCT02037243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disgust and Shame Based Intervention with Water Treatment
Description: Compound level meeting
Study NCT02037243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disgust and Shame Based Intervention with Water Treatment & Hand Washing
Description: Compound level meeting
Study NCT02932293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+DCV+SMV
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Study NCT00470795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)
Study NCT00470795 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo/sham acupuncture
Description: acupuncture at sham points without skin penetration
Study NCT02491931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplement/placebo intake
Description: Patients will receive either GLN or placebo prior to cardiovascular surgery under extracorporeal circulation, during 3 days and one final dose 4 hours prior to anesthesia.
Study NCT02491931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplement/placebo intake
Description: Patients will receive either GLN or placebo prior to cardiovascular surgery under extracorporeal circulation, during 3 days and one final dose 4 hours prior to anesthesia.
Study NCT02716909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Description: The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
Study NCT03007459 — intervention group
Intervention type: OTHER
Intervention: Psychological health
Description: Observing and measuring baseline, and changes in, psychological health through a fitness contest preparation period
Study NCT03007459 — intervention group
Intervention type: OTHER
Intervention: Physiological health
Description: Observing and measuring baseline, and changes in, physiological health through a fitness contest preparation period
Study NCT02359838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Geriatric Screening/Assessment
Description: All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
Study NCT02359838 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Baseline Geriatric Screening/Assessment
Description: All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
Study NCT02359838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Geriatrician Co-Management
Description: A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
Study NCT03797235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dominant Arm
Description: The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
Study NCT03797235 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-dominant arm
Description: The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
Study NCT03121183 — intervention group
Intervention type: DEVICE
Intervention: Laser sheath
Description: Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
Study NCT03121183 — intervention group
Intervention type: BEHAVIORAL
Intervention: Implantable Cardiac Device lead extraction
Description: Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
Study NCT03987412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with APP
Description: The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together. Then the lifestyle intervention will be launched by an APP that installed in participants' private mobile phones, including nutrition, exercise and phycological support. Nutrition guidance is conducted according to the Chinese Dietary Guide, Chinese and international guidelines of gestation diabetes management. Exercise support is given based on the Guidelines for National Fitness of China, Chinese and international guidelines of gestation diabetes. Phycological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP, and based on the data investigators will individualize the suggestions.
Study NCT02379741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADC-1013
Description: Agonistic human monoclonal IgG1 anti-CD40 antibody
Study NCT04517617 — intervention group
Intervention type: OTHER
Intervention: The level of air pollution
Description: The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.he perinatal period.
Study NCT03825601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET with [11C]Flumazenil
Description: 7T MRI sequences : TSE, T2w FLAIR GRE-T2\* and DIR 3T MRI sequences: T1, T2, T1 with gadolinium, magnetization transfer, diffusion weighted, resting state fMRI.
Study NCT03587675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EVH test
Study NCT01951014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Media Education
Description: Health messages provided via a private Facebook group and cellular text messages will be provided across gestation.
Study NCT03293095 — intervention group
Intervention type: PROCEDURE
Intervention: Standard Care
Description: The guidelines for the management according to the musculoskeletal disorder in primary care will be the treatment guidelines for the Standard Care.
Study NCT04759287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC VS
Description: The first group (VS group) will include patients undergoing awake intubation using the C-MAC VS
Study NCT04759287 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: flexible fibreoptic bronchoscope
Description: The second control group (FOB group) will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.
Study NCT01998477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIVc
Description: Madin Darby Canine Kidney (MDCK) cell culture derived subunit influenza vaccine TIVc contained the purified viral envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA) derived from 3 strains (including HA for each strain \[A/H1N1-like, A/H3N2-like, and B-like\]) intramuscular (IM) injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere
Study NCT01998477 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV
Description: A conventional egg derived subunit influenza vaccine (TIV) contained the purified viral envelope-glycoproteins, HA and NA derived from 3 strains (including HA for each strain \[A/ H1N1-like, A/H3N2-like, and B-like\]) IM injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere.
Study NCT00780585 — intervention group
Intervention type: DRUG
Intervention: SCH 900460
Description: Subjects who participated in previous trials of Org 24448 (SCH 900460)
Study NCT04357379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IQOS
Description: Participants will try an IQOS product and then take home the IQOS to sample for one week.
Study NCT01051375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Workshop and telephone support
Description: The intervention involves completion of a single workshop (delivered by a psychiatrist and adolescent health physician), provision of psycho educational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list.
Study NCT04015947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CelluTome® Epidermal Harvesting System
Description: split-thickness skin grafts from a matched bone marrow donor using the CelluTome® Epidermal Harvesting System
Study NCT02030145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Compressive Thoracic Lymphatic Pump
Description: This technique is a modification of the Classic Thoracic Lymphatic Pump where some pressure is maintained on the chest wall at the end of each exhalation and at the end of the third or fourth breathing cycle, during the inhalation phase, the hands are slowly removed from the chest wall, gradually releasing pressure on the chest without causing a sudden change in intrathoracic pressures.
Study NCT02030145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compressive Thoracic Lymphatic Pump
Description: This technique is a modification of the Classic Thoracic Lymphatic Pump where some pressure is maintained on the chest wall at the end of each exhalation and at the end of the third or fourth breathing cycle, during the inhalation phase, the hands are slowly removed from the chest wall, gradually releasing pressure on the chest without causing a sudden change in intrathoracic pressures.
Study NCT02030145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic Thoracic Lymphatic Pump
Description: This technique is well described in Chapter 68 of the Foundations for Osteopathic Medicine, 2nd Edition.
Study NCT02030145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Classic Thoracic Lymphatic Pump
Description: This technique is well described in Chapter 68 of the Foundations for Osteopathic Medicine, 2nd Edition.
Study NCT01574313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stellate ganglion block
Description: stellate ganglion block
Study NCT01574313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25mg, fludiazine
Description: 0.25mg of erispan@ (fludiazine), p.o. one dose only.
Study NCT01574313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25mg cephadol@ (diphenidol)
Description: 25mg cephadol@ (diphenidol) p.o. one dose only.
Study NCT01574313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200mg kentons@ (tocopherol nicotinate).
Description: 200mg kentons@ (tocopherol nicotinate) p.o. one dose only.
Study NCT04611711 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: decitabine＋ TQB2450 injection
Description: Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.
Study NCT04611711 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: decitabine＋ TQB2450 injection＋Anlotinib
Description: Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.~Anlotinib Hydrochloride is a multi-target receptor tyrosine kinase inhibitor with significant inhibitory activity against angiogenesis related kinases (VEGFR1/2/3, FGFR1/2/3, etc.) and other tumor cell proliferation-related kinases (PDGFR /, C-Kit, RET, etc.), which can play a dual role in anti-tumor angiogenesis and tumor growth inhibition.
Study NCT02519751 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D3 Creatine
Description: One dose of D3 Creatine (60mg capsule) given orally on Day 1
Study NCT02519751 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Participants will consume an individual dosed level of creatine, based on their estimated muscle mass in doses of 0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on a weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
Study NCT06130657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Maxillary Sinus Floor Elevation using surgical guide
Description: The surgical procedure begins with securing a prefabricated guide firmly to the surgical site. Implant positions are marked, and after guide removal, a crestal incision is made 1 mm palatal to the marked point, extending with sulcular and vertical incisions. A full-thickness mucoperiosteal flap is reflected to expose the maxillary sinus and alveolar crest. After readapting the surgical guide to the bone, implant positions are marked, and cutting edges are tracked. The lateral window is formed by extending and connecting mesial and distal borders, created using piezotome. The sinus membrane is carefully reflected and elevated with a surgical curette to avoid iatrogenic perforation. Implant fixtures are then placed using the identical surgical guide, followed by graft material placement beneath the elevated sinus membrane. If the bony plate is preserved, the lateral window is covered with the plate.
Study NCT06130657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Maxillary Sinus Floor Elevation without surgical guide
Description: The sinus's lateral wall is exposed through a crestal incision and a mucoperiosteal flap. A bony window is created, and upon its removability, the sinus floor is carefully elevated using sinus elevation curettes, taking care to avoid membrane perforation. In cases of perforation, a resorbable collagen membrane is applied to cover the hole. Implant osteotomies are then completed following the standard sequential placement protocol. Graft material, mixed with normal saline, is gently packed into the sinus to fill the cavity with bone substitute material and achieve the desired bone height. Finally, a resorbable membrane is placed on the outer surface of the window, and the flap is sutured for primary closure.
Study NCT03184909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocimum Sanctum
Description: Active capsules containing leaves of organically prepared ocimum sanctum
Study NCT03184909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules of look alike inert substance for control
Study NCT02687594 — intervention group
Intervention type: DRUG
Intervention: sucroferric oxyhydroxide
Description: The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.